The US Food and Drug Administration is planning to issue a draft guidance on the use of artificial intelligence in regulatory decision making by the end of the year. The move would be the most concrete oversight action to date by the agency, which has been ramping up its AI activities with discussion papers, workshops and collaborations.
US FDA Guidance On Artificial Intelligence For Regulatory Decision-Making Expected This Year
Draft guidance will offer a risk-based framework for accessing the credibility of AI and help ensure that AI models used to answer regulatory questions are sufficiently credible for a particular ‘context of use,’ CDER’s Tala Fakhouri says.
More from Digital Technologies
• By
To improve engagement with patient information, a UK ePI Task Force comprising PAGB, ABPI and BGMA is looking at how electronic patient information leaflets (ePILs) can be introduced in the country.
• By
Bayer hopes Impli's implantable hormone biosensor will reveal self-care opportunities in the areas of stress, sleep, weight management, cardiovascular health, women’s health, or bone health.
• By
Cork-based iron supplement manufacturer Solvotrin teams up with app developer Clue to offer consumers a free year's subscription to the latter's menstrual health app.
• By
In addition to its recently established Precision Health division, Bayer Consumer Health is using artificial intelligence to save time on routine tasks and to manage supply and demand, the firm’s head of digital transformation and IT, Cristina Nitulescu, tells HBW Insight.
More from HBW Insight
• By
Ulta Beauty, Inc. CEO Dave Kimbell retires after 11 years with the beauty retailer and is replaced by president and chief operating officer Kecia Steelman, as a strong holiday sales period prompts the firm to update its fiscal fourth quarter projections.
• By
In response to an IPA Europe complaint, European Ombudsman Emily O’Reilly finds that the Commission’s interpretation of EU food legislation in relation to probiotics is “reasonable and in line with the main goal of this legislation, which is to ensure a high level of consumer protection.”
• By
Final rule’s requirement that ACNU formulations also remain available as Rx generics could limit revenues for marketers of the nonprescription drugs while approvals of ACNU applications from studies with participants having drugs delivered to their homes may require marketers to limit distribution to direct-to-consumer without clearance for sales in retail stores.